Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Contact us

• Submission enquiries: bmccancer@biomedcentral.com
• General enquiries: ORSupport@springernature.com